Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort

Background and Objectives: Real-world evidence should reflect the evidence obtained from controlled trials; therefore, the study aimed to compare biosimilar adalimumab (bADA) to original adalimumab (oADA) in terms of efficacy and safety in a real-life national cohort of rheumatoid arthritis (RA) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Popescu, Claudiu Costinel, Mogoșan, Corina Delia, Enache, Luminița, Codreanu, Cătălin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784493/
https://www.ncbi.nlm.nih.gov/pubmed/36557052
http://dx.doi.org/10.3390/medicina58121851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784493/
https://www.ncbi.nlm.nih.gov/pubmed/36557052
http://dx.doi.org/10.3390/medicina58121851

Ejemplares similares